Coforge Navigates Board Shake-Up as Emkay Global Reaffirms 'BUY' with Upgraded Target

In the bustling world of Indian equities, where investor sentiment can often swing with the slightest whisper of change, Coforge has certainly been a focal point lately. You see, the IT services firm has recently grappled with some notable board resignations. Yet, here's the interesting bit: Emkay Global Financial, a prominent name in market analysis, isn't just holding steady; they've actually reaffirmed their 'BUY' recommendation for Coforge and, what's more, have even increased their target price to a solid ₹2,000 per share.

This revised target, up from their previous ₹1,800, isn't just a random number. It's built on a forward-looking valuation, rolling over to September 2028E EPS and applying a higher target multiple of 26 times, a nudge up from 24 times. Emkay's confidence, it seems, stems from a belief that the recent board exits, including those of former Chairman O P Bhatt and independent director D K Singh in September 2026, are isolated incidents. They view these as outcomes of an internal review process, rather than symptoms of a deeper, systemic governance issue that could undermine the company's core operations or its impressive growth outlook.

Now, let's talk about those board changes for a moment, because they certainly caused a stir. The resignations followed an internal audit by KPMG, which unearthed some rather concerning findings. Specifically, Board Evaluation Reports were being shared only with the Chairman and the Nomination and Remuneration Committee (NRC) Chair, not the wider board. And, perhaps most significantly, the audit revealed that the Chairman himself had received the lowest performance score, a detail that was reportedly kept from both the NRC and the full board.

Despite this unsettling backdrop, Coforge's management and its remaining independent board members have been quick to reassure everyone. They've explicitly stated that these internal issues have no bearing on the company's financial reporting, day-to-day operations, overall performance, or its future outlook. In fact, they've reiterated their financial guidance for FY27, projecting a healthy 20.5%-21% consolidated EBITDA margin. To bridge the gap, Vivek Sharma has been appointed as interim Chairperson until January 31, 2027, though he's recused himself from being considered for the permanent position.

The company hasn't just stopped at reassurances; they've taken proactive steps. The NRC has been reconstituted, now chaired by Beth Boucher and including independent directors Anil Chanana (who also chairs the Audit Committee) and Vivek Sharma. Moreover, Coforge has launched a global search, aided by Egon Zehnder, to find two additional independent directors. They're also implementing a structured process to select a new Board Chairperson, considering both existing and potential new independent directors. While D K Singh did cite "differences and tension" between independent and executive directors upon his departure, Coforge firmly rejected this claim as "unfounded," striving to maintain a united front.

From Emkay's perspective, all of this turbulence hasn't dimmed Coforge's fundamental shine. They've actually raised their revenue forecasts: FY27E by 0.8% to ₹2,51,017 million, FY28E by 1.1% to ₹2,91,313 million, and FY29E also by 1.1% to ₹3,29,718 million. And, they anticipate a robust FY27E EBITDA margin of 20.1%, a notable improvement from 18.6% in FY26. It's a clear signal that, for Emkay Global at least, Coforge remains a compelling investment, demonstrating resilience and a strong growth path even when facing internal headwinds. Other analysts seem to agree, with Jefferies also maintaining a 'Buy' with a target of ₹2,040, and Motilal Oswal targeting ₹2,200.